- Stocks
- Healthcare
- NASDAQ: NKTR

Price (delayed)

$0.718

Market cap

$135.87M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.97

Enterprise value

$179.14M

Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines.

Nektar Therapeutics's EPS has increased by 31% YoY and by 19% QoQ

The net income has grown by 30% year-on-year and by 19% since the previous quarter

Nektar Therapeutics's quick ratio has decreased by 16% YoY but it has increased by 13% from the previous quarter

Nektar Therapeutics's equity has decreased by 46% YoY and by 11% QoQ

The revenue has contracted by 10% YoY and by 3.1% from the previous quarter

What are the main financial stats of NKTR

Market
Valuations
Earnings

Shares outstanding

189.24M

Market cap

$135.87M

Enterprise value

$179.14M

Price to earnings (P/E)

N/A

Price to book (P/B)

0.37

Price to sales (P/S)

1.46

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.95

Revenue

$92.06M

EBIT

-$336.07M

EBITDA

-$323.04M

Free cash flow

-$296.49M

Per share
Balance sheet
Liquidity

EPS

-$1.97

Free cash flow per share

-$1.58

Book value per share

$1.95

Revenue per share

$0.49

TBVPS

$3.39

Total assets

$710.6M

Total liabilities

$343.96M

Debt

$131.5M

Equity

$366.64M

Working capital

$477.76M

Debt to equity

0.36

Current ratio

8

Quick ratio

7.49

Net debt/EBITDA

-0.13

Margins
Efficiency
Dividend

EBITDA margin

-350.9%

Gross margin

76.5%

Net margin

-400%

Operating margin

-408.6%

Return on assets

-43.6%

Return on equity

-79.8%

Return on invested capital

-46.1%

Return on capital employed

-52.3%

Return on sales

-365.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Nektar Therapeutics stock price performed over time

Intraday

-3.38%

1 week

-26.74%

1 month

-51.81%

1 year

-87.77%

YTD

-68.23%

QTD

-68.23%

How have Nektar Therapeutics's revenue and profit performed over time

Revenue

$92.06M

Gross profit

$70.42M

Operating income

-$376.17M

Net income

-$368.2M

Gross margin

76.5%

Net margin

-400%

The net income has grown by 30% year-on-year and by 19% since the previous quarter

The net margin has increased by 22% YoY and by 16% QoQ

The operating income is up by 16% year-on-year and by 14% since the previous quarter

The operating margin has grown by 11% from the previous quarter and by 7% YoY

What is Nektar Therapeutics's growth rate over time

What is Nektar Therapeutics stock price valuation

P/E

N/A

P/B

0.37

P/S

1.46

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

1.95

Nektar Therapeutics's EPS has increased by 31% YoY and by 19% QoQ

The P/B is 98% below the 5-year quarterly average of 17.6 and 75% below the last 4 quarters average of 1.5

Nektar Therapeutics's equity has decreased by 46% YoY and by 11% QoQ

The stock's P/S is 93% less than its 5-year quarterly average of 21.0 and 79% less than its last 4 quarters average of 7.0

The revenue has contracted by 10% YoY and by 3.1% from the previous quarter

How efficient is Nektar Therapeutics business performance

Nektar Therapeutics's ROE has decreased by 29% YoY but it has increased by 5% from the previous quarter

Nektar Therapeutics's return on sales has increased by 22% YoY and by 18% QoQ

The return on invested capital has declined by 12% year-on-year but it has grown by 8% since the previous quarter

NKTR's ROA is up by 9% from the previous quarter but it is down by 9% YoY

What is NKTR's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for NKTR.

How did Nektar Therapeutics financials performed over time

Nektar Therapeutics's total assets is 107% more than its total liabilities

Nektar Therapeutics's total assets has decreased by 36% YoY and by 9% from the previous quarter

The total liabilities has contracted by 21% YoY and by 7% from the previous quarter

The debt is 64% lower than the equity

The debt to equity has soared by 71% YoY and by 9% QoQ

Nektar Therapeutics's equity has decreased by 46% YoY and by 11% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.